News Center

ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
ACELYRIN, INC. Reports First Quarter 2023 Financial Results And Recent Highlights
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering
ACELYRIN, INC. Announces Launch of IPO Roadshow
ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy
Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors
ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio